A new mRNA vaccine for advanced melanoma is generating significant interest, but what does it actually mean for patients?

In the latest episode of Life by a Thousand Cuts, A/Prof Tony Dicker examines the recent trial of Moderna’s personalised mRNA vaccine, intismeran, in combination with pembrolizumab. He explains how the treatment is designed around the individual mutations in a patient’s melanoma, the early evidence for improved recurrence-free survival, and some of the practical challenges involved in producing a personalised vaccine.

For GPs, the key distinction is that this is not a vaccine to prevent melanoma. Rather, it is an emerging treatment approach for patients who already have advanced melanoma, and one that patients may increasingly ask about as more results receive media attention.

Prefer a visual format? Watch this podcast here.

Next steps in your learning journey

🎓 Micro-Courses in Skin Cancer Explore short, single-topic CPD modules for focused learning in skin cancer medicine and surgery. Complete in less than 10 hours from only $95. ➡️ Browse Micro-Courses >

🎓 Certificate Courses in Skin Cancer Explore our university-assured, structured pathway to elevate your knowledge in the diagnosis and treatment of skin cancer. ➡️ Explore full program >

🎓 HealthCert 365 subscription Prefer flexible learning across many topics? Access 4,000+ CPD hours on-demand with HealthCert 365 — anytime, any topic, one flat annual fee. ➡️ Discover HealthCert 365 >

This podcast series is designed to help you enhance your clinical decision-making, procedural skills, and confidence in skin cancer management. Focus on real-world cases, surgical techniques and tips, journal article reviews, diagnostic and management insights, and guest interviews with GPs and specialists.